A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT07553988 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: RS-113, 160 mg
DRUG: RS-113, 240 mg
DRUG: RS-113, 320 mg
DRUG: Abiraterone
DRUG: Prednisolone
DRUG: Androgen deprivation therapy (ADT)

Sponsor

R-Pharm International, LLC